1. Pink Sheet
  2. >>R&D
  3. >>Clinical Trials

Study Shows Effient Not Superior To Plavix, But Bleeding Risk Similar

 
• By Lisa LaMotta

A study published in the New England Journal of Medicine showed Effient was not superior to Plavix in treating patients who had not undergone revascularization.

Eli Lilly & Co./Daiichi Sankyo Co. Ltd.were not able to show Effient (prasugrel) was superior to Bristol-Myers Squibb Co./Sanofi’s Plavix (clopidogrel) in a head to head study, but the partners have gained evidence that the rates of major bleeding were similar – an outcome that could be used in Effient’s favor.

The TRILOGY ACS study was published in the New England Journal of Medicine on Aug. 26, in conjunction with its...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Orphan Drug Trial Sponsors ‘Playing Catch-Up’ With Regulators – But Automation Can Help

 
• By Eliza Slawther

Clinical trial sponsors in the rare disease space face “big safety demands” from regulators, which can be challenging for those with limited resources. A CRO founder makes the case for “embedding automation” into the clinical trial process to keep pace with regulatory requirements.

Nipah Vaccine With ‘Pandemic Potential’ Wins EMA PRIME Designation

 
• By Neena Brizmohun

The developers of the ChAdOx1 NipahB vaccine will be able to benefit from the early and enhanced support that the European Medicines Agency offers through its priority medicines scheme.

Elegy For SACHRP: US HHS Research Protection Panel Tackled Tough Pediatric Trial Questions

 
• By Bridget Silverman

The termination of the HHS Secretary’s Committee on Human Research Protections closed an important forum for discussing pediatrics and pregnancy in clinical trial design, a former SACHRP chair said.